Patent 9724195 was granted and assigned to Mitralign on August, 2017 by the United States Patent and Trademark Office.
The present teachings generally relate to translation catheter systems and method of using thereof in treating defective mitral valves. Specifically, a translation catheter system includes a catheter configured to move substantially laterally along the mitral annulus and the lateral movement of the catheter is substantially continuous and substantially adjustable. Accordingly, a method of using such a translation catheter includes advancing a first wire across the mitral annulus at a first treatment location, delivering a catheter at or near the first treatment location, moving the catheter substantially laterally to a second treatment location, and advancing a second wire across the mitral annulus, where the distance between the first and second treatment locations is substantially adjustable and optionally visualized.